GET DAILY SIGNALSCreative Medical Technology Holdings (CELZ) Q3 2026 Earnings Outlook
Key Takeaways
- Creative Medical Technology Holdings (CELZ) is expected to report results for the third quarter of fiscal 2026, the period ended September 30, 2026, on or around November 6, 2026.
- Wall Street's consensus estimate calls for a net loss of roughly -$0.24 per share, a notably narrower loss than the -$0.41 per share reported in the prior quarter.
- Revenue is expected to remain minimal, consistent with the company's clinical-stage status, where most funding goes toward research and development rather than product sales.
- Investors will closely watch operating expenses after selling, general, and administrative (SG&A) costs jumped about 48% year over year in the previous quarter due to a national marketing campaign.
- The company ended its most recent quarter with approximately $8.7 million in cash, a level that will frame questions about its near-term runway.
- Pipeline progress on the CELZ-201 CREATE-1 Type 1 Diabetes trial and the CELZ-201 ADAPT chronic lower back pain program remains a key catalyst to monitor.
Putting the Earnings in Context
Creative Medical Technology Holdings is a commercial-stage biotechnology company focused on regenerative therapies across immunotherapy, endocrinology, urology, neurology, and orthopedics. Because the company generates only minimal revenue from disposable stem cell concentration kits, its quarterly report serves less as a measure of sales momentum and more as a progress check on clinical development, spending discipline, and cash reserves. For investors, the release offers a snapshot of how efficiently management is advancing its lead programs, including its Type 1 Diabetes and chronic lower back pain trials, while preserving capital. Recent quarters have shown volatility in both reported losses and market reaction, making this update an important signal for the stock's near-term direction. I also checked this using Tickeron’s AI Screener to see how CELZ compares to others in the industry.
Analyst Forecasts for the Quarter
Analysts' consensus estimate for the third quarter of fiscal 2026 points to a net loss of approximately -$0.24 per share, which would mark a meaningful improvement from the -$0.41 per share reported for the second quarter. Revenue expectations remain negligible, reflecting the company's early commercial stage and its reliance on development-stage programs rather than significant product sales.
Recent history provides useful context. In the second quarter of fiscal 2026, CELZ reported a loss of -$0.41 per share, missing the -$0.39 consensus estimate. The prior quarter was slightly better, with a -$0.38 per share result that narrowly beat the -$0.39 estimate. The fourth quarter of fiscal 2025 showed a much wider loss of -$0.80 per share, well below the -$0.37 consensus. These swings highlight both the inherent variability of early-stage biotech accounting and the market's sensitivity to expense surprises, particularly the elevated marketing costs that pressured the most recent quarter.
Market Reaction and Sentiment
Sentiment heading into the third-quarter report is cautious. As a low-priced, small-cap biotechnology stock, CELZ tends to react sharply to surprises in both its reported losses and any updates on clinical programs. The previous quarter's miss, driven by higher marketing spend, underscored how quickly operating-cost decisions can influence investor confidence. Analysts expect a narrower loss this time, and the market will likely interpret the results in the context of whether the company is making tangible progress toward its clinical milestones while keeping expenses in check. Key risk factors include any unexpected jump in spending, a slower-than-expected pace of patient enrollment, or a weaker-than-anticipated cash position.
Forward Outlook and Key Factors to Monitor
Beyond the headline earnings per share figure, investors should watch how the company allocates capital across its lead programs. The CELZ-201 CREATE-1 trial for Type 1 Diabetes and the CELZ-201 ADAPT study for chronic lower back pain are central to the company's long-term thesis, and any update on enrollment, safety, or data timing could prove more consequential than the quarterly loss itself.
Spending trends will also be important. The prior quarter's sharp rise in SG&A expenses reflected a deliberate national marketing push, and investors will want to see whether that investment translates into clinical or commercial traction or whether it continues to weigh on the bottom line. At the same time, research and development costs may fluctuate as trials move between active treatment and follow-up phases.
Finally, the company's cash position of roughly $8.7 million at the end of the second quarter places a spotlight on its runway. Management's commentary around future financing, warrant activity, and cost controls will help investors gauge whether the company can fund its pipeline through upcoming catalysts without excessive dilution. These factors, rather than any single quarter's loss, are likely to shape the stock's trajectory in the months ahead. From what I see, monitoring these elements alongside broader market signals helps form a clearer picture.
Integrating AI Tools Into My Workflow
When evaluating names like CELZ, I often rely on Tickeron’s AI Daily Buy/Sell Signals to cross-check technical trends and sentiment shifts that might not be obvious from fundamentals alone. This approach helps me stay objective when reviewing quarterly updates and pipeline developments. It is a practical way to add another layer of data without replacing traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CELZ in +12.70% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CELZ advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CELZ's RSI Indicator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
CELZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELZ as a result. In 91 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CELZ turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELZ entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.546) is normal, around the industry mean (3.482). P/E Ratio (-0.303) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CELZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement